In terms of metabolic parameters, all the treated arms had beneficial changes in their HbA1c%, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels, with the Sema+-MSTN+-ActA arm, which showed the largest combination of fat decrease and lean mass increase, showing the biggest beneficial changes (Fig
Potential side effects, such as increased heart rate or sleep disturbances, require close medical supervision
It is segmented geographically, with specific market dynamics for each region
Mean reduction in total body fat mass was 33.9%
Patients on lower doses lose weight more slowly, full stop
It is notable that neither the GLP-1R antagonist exendin(939) nor the GRA REMD2.59 had any (major) effect on glucagon secretion at 1 mmol/l glucose, making it unlikely that glucagon secretion is under significant autocrine control by glucagon or GLP-1(736) [63, 64] from alpha cells